Literature DB >> 30705060

Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial.

Silvio E Inzucchi1, Christoph Wanner2, Uwe Hehnke3, Isabella Zwiener3, Stefan Kaspers3, Douglas Clark3, Jyothis T George3, Bernard Zinman4.   

Abstract

Entities:  

Year:  2019        PMID： 30705060     DOI： 10.2337/dc18-1355

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  8 in total

1.  Relationship Between SGLT-2i and Ocular Diseases in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Bin Zhou; Yetan Shi; Rongrong Fu; Haixiang Ni; Lihu Gu; Yuexiu Si; Mengting Zhang; Ke Jiang; Jingyi Shen; Xiangyuan Li; Xing Sun
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-26       Impact factor: 6.055

Review 2.  Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus.

Authors:  André J Scheen
Journal:  Nat Rev Endocrinol       Date:  2020-08-27       Impact factor: 43.330

Review 3.  Early microvascular complications in type 1 and type 2 diabetes: recent developments and updates.

Authors:  Kalie L Tommerdahl; Allison L B Shapiro; Edward J Nehus; Petter Bjornstad
Journal:  Pediatr Nephrol       Date:  2021-04-14       Impact factor: 3.714

Review 4.  Consensus recommendations for management of patients with type 2 diabetes mellitus and cardiovascular diseases.

Authors:  Alaaeldin Bashier; Azza Bin Hussain; Elamin Abdelgadir; Fatheya Alawadi; Hani Sabbour; Robert Chilton
Journal:  Diabetol Metab Syndr       Date:  2019-09-26       Impact factor: 3.320

5.  How and why SGLT2 inhibitors should be explored as potential treatment option in diabetic retinopathy: clinical concept and methodology.

Authors:  Marcus May; Theodor Framke; Bernd Junker; Carsten Framme; Amelie Pielen; Christoph Schindler
Journal:  Ther Adv Endocrinol Metab       Date:  2019-12-11       Impact factor: 3.565

6.  The Effect of Sodium-Dependent Glucose Cotransporter 2 Inhibitor Tofogliflozin on Neurovascular Coupling in the Retina in Type 2 Diabetic Mice.

Authors:  Junya Hanaguri; Harumasa Yokota; Akifumi Kushiyama; Sakura Kushiyama; Masahisa Watanabe; Satoru Yamagami; Taiji Nagaoka
Journal:  Int J Mol Sci       Date:  2022-01-25       Impact factor: 5.923

7.  Effects of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic retinopathy and its progression: A real-world Korean study.

Authors:  Yoo-Ri Chung; Kyoung Hwa Ha; Kihwang Lee; Dae Jung Kim
Journal:  PLoS One       Date:  2019-10-28       Impact factor: 3.240

8.  Differential Effects of Empagliflozin on Microvascular Complications in Murine Models of Type 1 and Type 2 Diabetes.

Authors:  Stephanie A Eid; Phillipe D O'Brien; Lucy M Hinder; John M Hayes; Faye E Mendelson; Hongyu Zhang; Lixia Zeng; Katharina Kretzler; Samanthi Narayanan; Steven F Abcouwer; Frank C Brosius Iii; Subramaniam Pennathur; Masha G Savelieff; Eva L Feldman
Journal:  Biology (Basel)       Date:  2020-10-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.